Shock Wave Therapy for Sural Myofascial Pain Associated to Chronic Heel Pain (NCT04385329) | Clinical Trial Compass
CompletedNot Applicable
Shock Wave Therapy for Sural Myofascial Pain Associated to Chronic Heel Pain
55 participantsStarted 2016-07-04
Plain-language summary
The aim of this randomized controlled study in to investigate if a shock wave treatment extended to the gastrocnemius-soleus trigger points (TrP) is more effective than a standard treatment exclusively targeted at the plantar fascia in a population affected by unilateral plantar fasciitis with concomitant sural myofascial pain syndrome.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult age (18 to 75 years) and written informed consent;
* Unilateral heel pain of four weeks or longer duration;
* Pain to digital pressure in the insertional area of the plantar fascia at the calcaneum;
* Sonographic examination showing a plantar fascia thickness greater than 3.8mm (see procedures for details);
* Concomitant presence of a sural myofascial pain syndrome (SMPS), diagnosed on the basis of the finding, at the physical examination, of trigger points of the gastrocnemius-soleus muscle complex, according to Travel and Simons' original description.
Exclusion Criteria:
* No corticosteroid injections or other physical therapies since the onset of the current pain episode (except pharmacological pain treatments and foot orthoses);
* No general contraindication to shock wave therapy (pregnancy, bleeding disorders or anticoagulant drug usage, cancer in the focal area);
* No clinical signs of lumbar radiculopathy at physical examination;
* No ankle osteoarthritis, diagnosed on the basis of clinical and radiographic findings;
* No previous fractures or surgery in the affected ankle and foot;
* No rheumatologic diseases, no plantar fibromatosis
What they're measuring
1
Change in FFI-foot function index
Timeframe: FFI was administered at baseline, at two months time point and at three months time point
Trial details
NCT IDNCT04385329
SponsorFondazione IRCCS Policlinico San Matteo di Pavia